ECSP088473A - FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB - Google Patents

FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB

Info

Publication number
ECSP088473A
ECSP088473A EC2008008473A ECSP088473A ECSP088473A EC SP088473 A ECSP088473 A EC SP088473A EC 2008008473 A EC2008008473 A EC 2008008473A EC SP088473 A ECSP088473 A EC SP088473A EC SP088473 A ECSP088473 A EC SP088473A
Authority
EC
Ecuador
Prior art keywords
crystal form
glass forms
warm
methyl
preparation
Prior art date
Application number
EC2008008473A
Other languages
English (en)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088473A publication Critical patent/ECSP088473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La invención se refiere a la forma de cristal-F, la forma de cristal-G, la forma de cristal-H, la forma de cristal-I, y la forma de cristal-K de la sal de adición de ácido metansulfónico de la 4-(4-metil-piperazin-1-ilmetil)-N-[4-metil-3-(4-(piridin-3-il)-pirimidin-2-ilamino)-fenil]-benzamida, a ciertos procesos para su preparación, a composiciones farmacéuticas que contienen estas formas de cristal, a su uso en métodos de diagnóstico o para el tratamiento terapéutico de animales de sangre caliente, y a su uso como un intermediario o para la preparación de preparaciones farmacéuticas para utilizarse en métodos de diagnóstico para el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
EC2008008473A 2005-11-25 2008-05-20 FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB ECSP088473A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001605P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
ECSP088473A true ECSP088473A (es) 2008-06-30

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008473A ECSP088473A (es) 2005-11-25 2008-05-20 FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB

Country Status (13)

Country Link
US (6) US7893076B2 (es)
EP (3) EP1960380A1 (es)
JP (2) JP5844508B2 (es)
KR (4) KR20130140909A (es)
CN (1) CN102351842B (es)
AU (2) AU2006316823A1 (es)
BR (1) BRPI0618993A2 (es)
CA (3) CA2824301C (es)
EC (1) ECSP088473A (es)
MY (1) MY146403A (es)
NO (1) NO20082684L (es)
UY (1) UY29964A1 (es)
WO (1) WO2007059963A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
CA2824301C (en) * 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate
WO2009042809A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
WO2015081175A1 (en) * 2013-11-26 2015-06-04 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles
JP7263784B2 (ja) 2019-01-11 2023-04-25 日本精工株式会社 自在継手用ヨーク

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
US7300938B2 (en) * 2003-06-02 2007-11-27 Hetero Drugs Limited Polymorphs of imatinib mesylate
AR047530A1 (es) 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
CA2555804C (en) * 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
BRPI0511805A (pt) 2004-06-04 2008-01-15 Bioniche Life Sciences Inc uso de imatinib para tratar distúrbios hepáticos e infecções virais
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
AR055613A1 (es) * 2005-08-26 2007-08-29 Novartis Ag Formas cristalinas delta y epsilon de mesilato de imatinib
CA2824301C (en) * 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
US20110171301A1 (en) 2011-07-14
US20080268040A1 (en) 2008-10-30
KR20130141712A (ko) 2013-12-26
KR20130140909A (ko) 2013-12-24
KR20130137721A (ko) 2013-12-17
CA2824301C (en) 2016-01-12
MY146403A (en) 2012-08-15
JP2014074067A (ja) 2014-04-24
AU2006316823A1 (en) 2007-05-31
EP2546248A1 (en) 2013-01-16
JP2009517353A (ja) 2009-04-30
NO20082684L (no) 2008-08-15
EP1960380A1 (en) 2008-08-27
CA2628330C (en) 2015-06-16
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
CA2824307C (en) 2016-03-29
CN102351842B (zh) 2014-07-23
KR20080078804A (ko) 2008-08-28
UY29964A1 (es) 2007-06-29
US20120015955A1 (en) 2012-01-19
US8592440B2 (en) 2013-11-26
CA2824307A1 (en) 2007-05-31
CN102351842A (zh) 2012-02-15
EP2578580A1 (en) 2013-04-10
AU2011201286A1 (en) 2011-04-07
WO2007059963A1 (en) 2007-05-31
CA2824301A1 (en) 2007-05-31
US20130224288A1 (en) 2013-08-29
US8846706B2 (en) 2014-09-30
US8507515B2 (en) 2013-08-13
CA2628330A1 (en) 2007-05-31
US8198289B2 (en) 2012-06-12
JP5844508B2 (ja) 2016-01-20
US20120226038A1 (en) 2012-09-06
US20120015027A1 (en) 2012-01-19
BRPI0618993A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
ECSP088473A (es) FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
CY1124519T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ (S)-4-(8-ΑΜΙΝΟ-3-(1-(ΒΟΥΤ-2-ΥΝΟΫΛΟ)ΠΥΡΡΟΛΙΔΙΝ-2-ΥΛΟ) ΙΜΙΔΑΖΟ[1,5-α|ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ) ΒΕΝΖΑΜΙΔΙΟΥ
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CO6382134A2 (es) Sales y formas de cristal del 2-metil-2-[4-(metil-2-oxo-8-quinolin-3-3il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]propionitrilo
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
SV2010003714A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CR9881A (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
SV2007002813A (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
AR057239A1 (es) Inmunoglobulinas
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
CL2016002510A1 (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano [3,4-d][1,3] tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas.